Compare $CTMX vs $MNPR | Chartloom

Compare

$CTMX vs $MNPR

CytomX Therapeutics Inc · Monopar Therapeutics Inc

CTMX

CytomX Therapeutics Inc

MNPR

Monopar Therapeutics Inc

Compare $CTMX vs $MNPR

Comparing CytomX Therapeutics Inc and Monopar Therapeutics Inc

CTMXCytomX Therapeutics Inc

MNPRMonopar Therapeutics Inc

CTMXCytomX Therapeutics Inc

Market cap

$559M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

32.52x

Rev growth (TTM)

-87.0%

YTD performance

-39.5%

52W performance

-23.7%

FCF yield

-14.8%

MNPRMonopar Therapeutics Inc

Market cap

$529M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

48.37x

Rev growth (TTM)

—

YTD performance

19.6%

52W performance

-19.9%

FCF yield

-2.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CTMX

MNPR

Detailed metrics comparison

CTMX

CytomX Therapeutics Inc

MNPR

Monopar Therapeutics Inc

Market Cap

CTMX$559M

MNPR$529M

Enterprise Value

CTMX$542M

MNPR$476M

Price

CTMX$2.57

MNPR$78.96

P/E Ratio

CTMXN/A

MNPRN/A

P/S Ratio

CTMX30.57x

MNPR0.00x

EV/Sales

CTMX29.63x

MNPR0.00x

EV/EBITDA

CTMX22.17x

MNPR0.00x

P/B Ratio

CTMX1.85x

MNPR4.00x

P/FCF Ratio

CTMXN/A

MNPRN/A

EV/FCF

CTMX-6.55x

MNPR-39.10x

PEG Ratio

CTMXN/A

MNPRN/A

Forward P/E (NTM)

CTMXN/A

MNPRN/A

Forward P/S (NTM)

CTMX32.52x

MNPR48.37x

Revenue (TTM)

CTMX$18M

MNPR$0

Revenue Growth (YoY)

CTMX-87.0%

MNPRN/A

Forward Rev Growth

CTMX35.7%

MNPR327.6%

Gross Margin (TTM)

CTMX0.0%

MNPR0.0%

Operating Margin (TTM)

CTMX0.0%

MNPR0.0%

EBITDA Margin (TTM)

CTMX-471.6%

MNPR0.0%

Net Margin (TTM)

CTMX-451.6%

MNPR0.0%

FCF Margin (TTM)

CTMX-452.1%

MNPRN/A

Net Income (TTM)

CTMX$-83M

MNPR$-18M

FCF (TTM)

CTMX$-83M

MNPR$-12M

EPS (TTM)

CTMX-$0.38

MNPR-$2.09

ROE (TTM)

CTMX-3846.0%

MNPR-1308.0%

ROA (TTM)

CTMX-3033.0%

MNPR-1279.0%

ROIC (TTM)

CTMX-3846.0%

MNPR-1308.0%

Cash

CTMX$17M

MNPR$53M

Debt

CTMX$0

MNPR$0

Net Cash/Debt

CTMX$17M

MNPR$53M

Current Ratio (TTM)

CTMX9.36x

MNPR33.56x

Quick Ratio (TTM)

CTMX9.25x

MNPR33.56x

Debt/Equity (TTM)

CTMX0.00x

MNPR0.00x

Debt/Assets (TTM)

CTMX0.0%

MNPR0.0%

Interest Coverage (TTM)

CTMXN/A

MNPRN/A

Net Debt/EBITDA (TTM)

CTMX0.00x

MNPR0.00x

Beta

CTMX2.26

MNPR1.54

52W Performance

CTMX-23.7%

MNPR-19.9%

YTD Performance

CTMX-39.5%

MNPR19.6%

% from 52W High

CTMX-68.7%

MNPR-36.7%

% from 52W Low

CTMX5.8%

MNPR57.7%

Asset Turnover (TTM)

CTMX0.07x

MNPR0.00x

FCF Yield (TTM)

CTMX-14.8%

MNPR-2.3%

Earnings Yield (TTM)

CTMX-14.8%

MNPR-3.4%

Dividend Yield (TTM)

CTMXN/A

MNPRN/A

Rule of 40

CTMX-539.1

MNPR0.0

EV/GP/RG

CTMXN/A

MNPRN/A

Ticker research

View CTMX research View MNPR research

Metric	CTMX CytomX Therapeutics Inc	MNPR Monopar Therapeutics Inc
Market & Valuation
Market Cap	$559M	$529M
Enterprise Value	$542M	$476M
Price	$2.57	$78.96
P/E Ratio	N/A	N/A
P/S Ratio	30.57x	0.00x
EV/Sales	29.63x	0.00x
EV/EBITDA	22.17x	0.00x
P/B Ratio	1.85x	4.00x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.55x	-39.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	32.52x	48.37x
Revenue & Growth
Revenue (TTM)	$18M	$0
Revenue Growth (YoY)	-87.0%	N/A
Forward Rev Growth	35.7%	327.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-471.6%	0.0%
Net Margin (TTM)	-451.6%	0.0%
FCF Margin (TTM)	-452.1%	N/A
Net Income (TTM)	$-83M	$-18M
FCF (TTM)	$-83M	$-12M
EPS (TTM)	-$0.38	-$2.09
ROE (TTM)	-3846.0%	-1308.0%
ROA (TTM)	-3033.0%	-1279.0%
ROIC (TTM)	-3846.0%	-1308.0%
Financial Health
Cash	$17M	$53M
Debt	$0	$0
Net Cash/Debt	$17M	$53M
Current Ratio (TTM)	9.36x	33.56x
Quick Ratio (TTM)	9.25x	33.56x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.26	1.54
52W Performance	-23.7%	-19.9%
YTD Performance	-39.5%	19.6%
% from 52W High	-68.7%	-36.7%
% from 52W Low	5.8%	57.7%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.00x
FCF Yield (TTM)	-14.8%	-2.3%
Earnings Yield (TTM)	-14.8%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-539.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CTMX research	View MNPR research

Valuation

P/S Ratio

MNPR

0.00x

CTMX

30.57x

EV/FCF

MNPR

-39.10x

CTMX

-6.55x

Growth & revenue

Revenue Growth TTM

CTMX

-87.0%

Forward Revenue Growth

MNPR

327.6%

CTMX

35.7%

Profitability & performance

Gross Margin

CTMX

0.0%

MNPR

0.0%

ROE

MNPR

-1308.0%

CTMX

-3846.0%

FCF Yield %

MNPR

-2.3%

CTMX

-14.8%

52-Week Performance

MNPR

-19.9%

CTMX

-23.7%

Detailed metrics comparison

CTMX

CytomX Therapeutics Inc

MNPR

Monopar Therapeutics Inc

Market Cap

CTMX$559M

MNPR$529M

Enterprise Value

CTMX$542M

MNPR$476M

Price

CTMX$2.57

MNPR$78.96

P/E Ratio

CTMXN/A

MNPRN/A

P/S Ratio

CTMX30.57x

MNPR0.00x

EV/Sales

CTMX29.63x

MNPR0.00x

EV/EBITDA

CTMX22.17x

MNPR0.00x

P/B Ratio

CTMX1.85x

MNPR4.00x

P/FCF Ratio

CTMXN/A

MNPRN/A

EV/FCF

CTMX-6.55x

MNPR-39.10x

PEG Ratio

CTMXN/A

MNPRN/A

Forward P/E (NTM)

CTMXN/A

MNPRN/A

Forward P/S (NTM)

CTMX32.52x

MNPR48.37x

Revenue (TTM)

CTMX$18M

MNPR$0

Revenue Growth (YoY)

CTMX-87.0%

MNPRN/A

Forward Rev Growth

CTMX35.7%

MNPR327.6%

Gross Margin (TTM)

CTMX0.0%

MNPR0.0%

Operating Margin (TTM)

CTMX0.0%

MNPR0.0%

EBITDA Margin (TTM)

CTMX-471.6%

MNPR0.0%

Net Margin (TTM)

CTMX-451.6%

MNPR0.0%

FCF Margin (TTM)

CTMX-452.1%

MNPRN/A

Net Income (TTM)

CTMX$-83M

MNPR$-18M

FCF (TTM)

CTMX$-83M

MNPR$-12M

EPS (TTM)

CTMX-$0.38

MNPR-$2.09

ROE (TTM)

CTMX-3846.0%

MNPR-1308.0%

ROA (TTM)

CTMX-3033.0%

MNPR-1279.0%

ROIC (TTM)

CTMX-3846.0%

MNPR-1308.0%

Cash

CTMX$17M

MNPR$53M

Debt

CTMX$0

MNPR$0

Net Cash/Debt

CTMX$17M

MNPR$53M

Current Ratio (TTM)

CTMX9.36x

MNPR33.56x

Quick Ratio (TTM)

CTMX9.25x

MNPR33.56x

Debt/Equity (TTM)

CTMX0.00x

MNPR0.00x

Debt/Assets (TTM)

CTMX0.0%

MNPR0.0%

Interest Coverage (TTM)

CTMXN/A

MNPRN/A

Net Debt/EBITDA (TTM)

CTMX0.00x

MNPR0.00x

Beta

CTMX2.26

MNPR1.54

52W Performance

CTMX-23.7%

MNPR-19.9%

YTD Performance

CTMX-39.5%

MNPR19.6%

% from 52W High

CTMX-68.7%

MNPR-36.7%

% from 52W Low

CTMX5.8%

MNPR57.7%

Asset Turnover (TTM)

CTMX0.07x

MNPR0.00x

FCF Yield (TTM)

CTMX-14.8%

MNPR-2.3%

Earnings Yield (TTM)

CTMX-14.8%

MNPR-3.4%

Dividend Yield (TTM)

CTMXN/A

MNPRN/A

Rule of 40

CTMX-539.1

MNPR0.0

EV/GP/RG

CTMXN/A

MNPRN/A

Ticker research

View CTMX research View MNPR research

Metric	CTMX CytomX Therapeutics Inc	MNPR Monopar Therapeutics Inc
Market & Valuation
Market Cap	$559M	$529M
Enterprise Value	$542M	$476M
Price	$2.57	$78.96
P/E Ratio	N/A	N/A
P/S Ratio	30.57x	0.00x
EV/Sales	29.63x	0.00x
EV/EBITDA	22.17x	0.00x
P/B Ratio	1.85x	4.00x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.55x	-39.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	32.52x	48.37x
Revenue & Growth
Revenue (TTM)	$18M	$0
Revenue Growth (YoY)	-87.0%	N/A
Forward Rev Growth	35.7%	327.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-471.6%	0.0%
Net Margin (TTM)	-451.6%	0.0%
FCF Margin (TTM)	-452.1%	N/A
Net Income (TTM)	$-83M	$-18M
FCF (TTM)	$-83M	$-12M
EPS (TTM)	-$0.38	-$2.09
ROE (TTM)	-3846.0%	-1308.0%
ROA (TTM)	-3033.0%	-1279.0%
ROIC (TTM)	-3846.0%	-1308.0%
Financial Health
Cash	$17M	$53M
Debt	$0	$0
Net Cash/Debt	$17M	$53M
Current Ratio (TTM)	9.36x	33.56x
Quick Ratio (TTM)	9.25x	33.56x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.26	1.54
52W Performance	-23.7%	-19.9%
YTD Performance	-39.5%	19.6%
% from 52W High	-68.7%	-36.7%
% from 52W Low	5.8%	57.7%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.00x
FCF Yield (TTM)	-14.8%	-2.3%
Earnings Yield (TTM)	-14.8%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-539.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CTMX research	View MNPR research